Sign in
KIN Stock Price, Chart, Stats & News
Kindred Biosciences, Inc.
Save
–
Market cap
–
Current P/E
–
Forward P/E
KIN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 89.03% |
Operating margin | -47.36% |
Pretax margin | -51.69% |
Net margin | -56.03% |
Effective tax rate | -8.39% |
ROA | -24.66% |
ROE | -31.62% |
D/E | 0.30x |
Interest coverage ratio | -10.92x |
KIN valuation
P/E | – |
P/S | – |
P/B | 5.39x |
P/CF | -36.87x |
P/FCF | – |
P/OCF | -36.87x |
PEG | -0.15x |
EV multiple | 0.58x |
About
Kindred Biosciences, Inc. is a biopharmaceutical firm dedicated to the advancement of biological therapies specifically for companion animals. The company maintains an extensive pipeline of innovative biologics, spanning diverse therapeutic categories, underpinned by a robust intellectual property portfolio. Key development programs include treatments for canine atopic dermatitis, utilizing both interleukin-31 and interleukin-4R, as well as KIND-030 to combat parvovirus in dogs.
Similar securities
Based on sector and market capitalization
Report issue